390 related articles for article (PubMed ID: 17200425)
1. Analysis of empiric antimicrobial strategies for cellulitis in the era of methicillin-resistant Staphylococcus aureus.
Phillips S; MacDougall C; Holdford DA
Ann Pharmacother; 2007 Jan; 41(1):13-20. PubMed ID: 17200425
[TBL] [Abstract][Full Text] [Related]
2. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.
Grim SA; Rapp RP; Martin CA; Evans ME
Pharmacotherapy; 2005 Feb; 25(2):253-64. PubMed ID: 15767239
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.
Patanwala AE; Erstad BL; Nix DE
Curr Med Res Opin; 2007 Jan; 23(1):185-93. PubMed ID: 17257479
[TBL] [Abstract][Full Text] [Related]
4. Empiric outpatient therapy with trimethoprim-sulfamethoxazole, cephalexin, or clindamycin for cellulitis.
Khawcharoenporn T; Tice A
Am J Med; 2010 Oct; 123(10):942-50. PubMed ID: 20920697
[TBL] [Abstract][Full Text] [Related]
5. Oral antibiotic treatment for methicillin-resistant Staphylococcus aureus skin and soft tissue infections: review of the literature.
Khawcharoenporn T; Alan T
Hawaii Med J; 2006 Oct; 65(10):290-3. PubMed ID: 17194061
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model.
Bounthavong M; Hsu DI; Okamoto MP
Int J Clin Pract; 2009 Mar; 63(3):376-86. PubMed ID: 19222624
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
De Cock E; Sorensen S; Levrat F; Besnier JM; Dupon M; Guery B; Duttagupta S
Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
[TBL] [Abstract][Full Text] [Related]
8. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation.
Miller LG; Perdreau-Remington F; Bayer AS; Diep B; Tan N; Bharadwa K; Tsui J; Perlroth J; Shay A; Tagudar G; Ibebuogu U; Spellberg B
Clin Infect Dis; 2007 Feb; 44(4):471-82. PubMed ID: 17243048
[TBL] [Abstract][Full Text] [Related]
9. [The rate of inducible clindamycin resistance and susceptibilities to other antimicrobial agents in staphylococci].
Oğuz VA; Yapar N; Sezak N; Cavuş SA; Kurutepe S; Peksel H; Cakir N; Yüce A
Mikrobiyol Bul; 2009 Jan; 43(1):37-44. PubMed ID: 19334378
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and therapeutic evaluation of community-acquired methicillin-resistant Staphylococcus Aureus (MRSA) skin and soft tissue infections in the emergency department.
Walraven CJ; Lingenfelter E; Rollo J; Madsen T; Alexander DP
J Emerg Med; 2012 Apr; 42(4):392-9. PubMed ID: 21524884
[TBL] [Abstract][Full Text] [Related]
11. Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults.
Giordano PA; Elston D; Akinlade BK; Weber K; Notario GF; Busman TA; Cifaldi M; Nilius AM
Curr Med Res Opin; 2006 Dec; 22(12):2419-28. PubMed ID: 17257456
[TBL] [Abstract][Full Text] [Related]
12. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus.
Elliott DJ; Zaoutis TE; Troxel AB; Loh A; Keren R
Pediatrics; 2009 Jun; 123(6):e959-66. PubMed ID: 19470525
[TBL] [Abstract][Full Text] [Related]
13. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
[TBL] [Abstract][Full Text] [Related]
14. The role of primary care prescribers in the diagnosis and management of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
Lawrence KR; Golik MV; Davidson L
Am J Ther; 2009; 16(4):333-8. PubMed ID: 19617720
[TBL] [Abstract][Full Text] [Related]
15. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome.
Ruhe JJ; Smith N; Bradsher RW; Menon A
Clin Infect Dis; 2007 Mar; 44(6):777-84. PubMed ID: 17304447
[TBL] [Abstract][Full Text] [Related]
16. Oral beta-lactams applied to uncomplicated infections of skin and skin structures.
Jacobs MR; Jones RN; Giordano PA
Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):55S-65S. PubMed ID: 17292581
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of community-acquired methicillin-resistant Staphylococcus aureus in a private dermatology office.
Bruce AM; Spencer JM
J Drugs Dermatol; 2008 Aug; 7(8):751-5. PubMed ID: 18720691
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic-resistant Staphylococcus aureus in community-acquired pediatric neck abscesses.
Guss J; Kazahaya K
Int J Pediatr Otorhinolaryngol; 2007 Jun; 71(6):943-8. PubMed ID: 17418426
[TBL] [Abstract][Full Text] [Related]
19. No decrease in clindamycin susceptibility despite increased use of clindamycin for pediatric community-associated methicillin-resistant Staphylococcus aureus skin infections.
Szczesiul JM; Shermock KM; Murtaza UI; Siberry GK
Pediatr Infect Dis J; 2007 Sep; 26(9):852-4. PubMed ID: 17721387
[TBL] [Abstract][Full Text] [Related]
20. Management of community-associated methicillin-resistant Staphylococcus aureus infections in children.
Le J; Lieberman JM
Pharmacotherapy; 2006 Dec; 26(12):1758-70. PubMed ID: 17125437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
